STM JOURNALS

Research & Reviews: A Journal of
Drug Design & Discovery

ISSN: 2349-9036
Volume 11, Issue 3, 2024
September–December
DOI (Journal): 10.37591/RRJoDDD

https://journals.stmjournals.com/rrjoddd/

Review RRJoDDD

Review on Computer-Aided Drug Design in RAS Inhibitor Discovery

Mohd. Wasiullah[1], Piyush Yadav[2], Alqama Zehra[3], Satish Kumar Yadav[4,*], Sushil Yadav[5]

Abstract

This review explores the utilization of computer-aided drug design (CADD) methodologies in the discovery of inhibitors targeting the RAS pathway, a pivotal signaling cascade implicated in various cancers. Through an extensive examination of computational tools, methodologies, challenges, and recent advancements, this review aims to provide insights into the role of CADD in accelerating RAS inhibitor discovery. The discovery of effective inhibitors targeting the RAS pathway is of paramount importance in cancer therapeutics, given the critical role of RAS proteins in oncogenesis. Computer-aided drug design (CADD) methodologies have emerged as indispensable tools in accelerating the identification and optimization of RAS inhibitors. This review provides a comprehensive overview of the applications of CADD in RAS inhibitor discovery, encompassing molecular modeling, virtual screening, machine learning, and structural biology techniques. Through an exploration of recent advancements, challenges, and opportunities in the field, this review aims to elucidate the potential of CADD in driving innovation and accelerating the development of novel therapeutics for RAS-driven cancers.

Keywords: RAS pathway, computer-aided drug design (CADD), RAS inhibitors, molecular modelling, virtual screening, machine learning, structural biology, cancer therapeutics, precision oncology, drug discovery

INTRODUCTION

One of the most important problems facing modern medicine remains the search for effective cancer treatment. Among the numerous molecular pathways implicated in cancer development and progression, the RAS pathway stands out as a key player due to its critical role in regulating cell proliferation, survival, and differentiation [1]. Dysregulation of the RAS pathway, often resulting from mutations in RAS genes, is implicated in a wide range of human cancers, including pancreatic, colorectal, and lung cancers [2]. Despite its significance as a therapeutic target, direct inhibition of RAS proteins has long been considered challenging due to their elusive nature and lack of well-defined binding pockets for small-molecule inhibitors. However, recent advancements in computational methodologies, particularly in the field of computer-aided drug design (CADD), have opened new avenues for RAS inhibitor discovery [1].

***Author for Correspondence**
Satish Kumar Yadav
E-mail: slk.pharma@gmail.com

[1]Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[2]Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[3]Research Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[4]Associate Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[5]Lecturer, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: May 10, 2024
Accepted Date: May 14, 2024
Published Date: November 02, 2024

Citation: Mohd. Wasiullah, Piyush Yadav, Alqama Zehra, Satish Kumar Yadav, Sushil Yadav. Review on Computer-Aided Drug Design in RAS Inhibitor Discovery. Research & Reviews: A Journal of Drug Design & Discovery. 2024; 11(3): 7–14p.

Importance of Developing RAS Inhibitors

The urgent need for effective RAS inhibitors stems from the high prevalence of RAS mutations in human cancers, as well as the limited success of existing therapeutic interventions in targeting

RAS-driven tumors [3]. Increased risk of metastasis, resistance to conventional chemotherapy and targeted therapies, and poor prognosis are all associated with RAS mutations [2]. The discovery of potent and selective RAS inhibitors holds great promise for improving patient outcomes and addressing unmet therapeutic needs in cancer [4].

Role of Computational Methods in Accelerating Drug Discovery

Computational techniques have become essential tools in modern medicine, providing efficient and cost-effective methods for finding and enhancing treatment options [2]. In the context of RAS inhibitor discovery, computational approaches play a crucial role in rationalizing the design, screening, and optimization of small-molecule inhibitors targeting RAS proteins [4]. Using computer modeling, virtual screening, molecular dynamics simulations, and machine learning algorithms, copper compounds with good chemical properties and therapeutic properties can be rapidly identified [1].

RAS BIOLOGY AND STRUCTURE

The RAS pathway constitutes a complex signaling network that regulates fundamental cellular processes, including proliferation, differentiation, and survival [4]. Central to this pathway are the RAS proteins – HRAS, KRAS, and NRAS – which act as molecular switches, cycling between an active (GTP-bound) and inactive (GDP-bound) state to transduce extracellular signals to downstream effectors. Dysregulation of RAS signaling, often resulting from mutations in RAS genes, is a hallmark of many human cancers, driving aberrant cell growth and tumor progression [5].

Structural Features of RAS Proteins

RAS proteins are small GTPases consisting of conserved structural domains, including the GTPase domain, Switch I and Switch II regions, and C-terminal hypervariable region (HVR) [6]. The GTPase domain harbors the nucleotide-binding site and catalyzes the hydrolysis of GTP to GDP, thereby regulating RAS activity [7]. The Switch regions undergo conformational changes upon nucleotide binding, facilitating interactions with effector proteins and downstream signaling [3].

Cellular Signaling Pathways

RAS proteins transmit signals to downstream molecules, such as the RAF-MEK-ERK and PI3K-AKT pathways that regulate cell proliferation, survival, and metabolism [8]. Activation of these pathways promotes oncogenic transformation and tumor growth, making RAS proteins attractive targets for cancer therapy [9]. However, the dynamic nature of RAS signaling and the complexity of its downstream effectors pose significant challenges for drug discovery efforts [10].

RAS Mutations in Cancer

RAS mutations are among the most prevalent oncogenic alterations in human cancers, occurring in approximately one-third of all malignancies [11]. Mutant RAS proteins exhibit constitutive activation, leading to sustained downstream signaling and malignant transformation [3]. The most common RAS mutations involve amino acid substitutions at codons 12, 13, or 61, which impair GTP hydrolysis and lock RAS proteins in their active state [8]. These mutations are associated with aggressive tumor phenotypes, therapeutic resistance, and poor patient prognosis [11].

COMPUTER-AIDED DRUG DESIGN OVERVIEW

"Computer-aided drug design" (CADD) includes the use of a wide range of computer methods and tools to accelerate drug discovery [5]. By leveraging computational models, simulations, and algorithms, researchers can rationalize the design, screening, and optimization of potential drug candidates in a cost-effective and time-efficient manner [12]. In the context of RAS inhibitor

discovery, CADD offers a powerful approach for overcoming the challenges associated with targeting RAS proteins and identifying selective inhibitors with desirable pharmacological properties [13].

Molecular Modeling Techniques

Molecular modeling techniques form the cornerstone of CADD workflows, allowing researchers to predict the three-dimensional structures of biomolecular targets and their interactions with small-molecule ligands [13]. Molecular docking, one of the most widely used techniques, predicts the binding modes and binding affinities of ligands to target proteins by exploring their complementary shape and electrostatic interactions [1]. In contrast, molecular dynamics simulations provide insight into the dynamic behavior of biomolecular systems over time and reveal conformational changes and ligand-binding events at the atomic level. Additionally, quantitative structure-activity relationship (QSAR) analysis enables the correlation of chemical structure with biological activity, guiding the rational design and optimization of lead compounds [10].

Virtual Screening Strategies

Virtual screening is a computational method for prioritizing hybrid libraries and identifying potential compounds that are highly related to target proteins [14]. Ligand-based virtual screening methods, such as pharmacophore modeling and similarity searching, rely on the comparison of molecular features or chemical fingerprints to identify structurally diverse compounds with similar biological activity to known inhibitors [2]. Structure-based virtual screening, on the other hand, involves docking large compound libraries into the binding site of the target protein and ranking them based on their predicted binding affinities [5]. These virtual screening strategies enable researchers to efficiently explore chemical space and identify lead compounds for experimental validation [15].

A Combination of Computational and Experimental Methods

An integrated approach that combines computational and experimental techniques is crucial for the successful discovery and optimization of RAS inhibitors [13]. Once new compounds with increased potency, selectivity, and pharmacokinetics are developed, they can be synthesized and their biological activity verified experimentally. This process is guided by computer prediction [16]. Repeated computational modeling, synthetic synthesis, and biological testing enable the design and optimization of copper compounds, ultimately leading to the development of clinically relevant RAS inhibitors [2].

TARGETING RAS: CHALLENGES AND OPPORTUNITIES

Targeting RAS proteins presents both significant challenges and promising opportunities in the field of drug discovery [3]. In this section, we will explore the complexities associated with inhibiting RAS signaling, as well as the innovative strategies and emerging opportunities for developing effective RAS inhibitors [9].

Historical Challenges in RAS Targeting

Historically, RAS proteins have been considered “undruggable” due to their elusive nature and lack of well-defined binding pockets for small-molecule inhibitors [8]. The high affinity of RAS for GTP, coupled with its intrinsic conformational plasticity, poses significant challenges for designing molecules that can effectively disrupt RAS signaling [10]. The failure of previous RAS-focused drug screens highlights the need for sophisticated solutions to these problems [11].

Allosteric Inhibition of RAS

One promising strategy for targeting RAS involves allosteric inhibition, which involves disrupting protein-protein interactions or inducing conformational changes to inhibit RAS signaling [14]. Allosteric binding sites on RAS proteins, distinct from the GTP-binding pocket, offer opportunities for designing selective inhibitors that modulate RAS activity without directly interfering with nucleotide binding [6]. By targeting allosteric sites, researchers can potentially overcome the limitations associated with traditional orthosteric inhibitors and develop novel therapeutics for RAS-driven cancers [13].

Covalent Targeting Strategies

Covalent targeting represents another innovative approach for irreversibly inhibiting RAS proteins by forming covalent bonds with specific amino acid residues. Covalent inhibitors exploit reactive cysteine residues within the RAS protein, particularly in mutant forms of RAS, to covalently modify the protein and disrupt its function. These irreversible inhibitors offer potential advantages in terms of potency, selectivity, and duration of action, making them attractive candidates for therapeutic intervention [17].

STRUCTURAL BIOLOGY AND RAS INHIBITOR DESIGN

Understanding the three-dimensional structure of RAS proteins and their complexity with small-molecule inhibitors is critical to guiding rational drug development efforts [15]. Structural biology techniques provide invaluable insights into the conformational dynamics, binding sites, and interaction interfaces of RAS proteins, facilitating the design and optimization of selective inhibitors [16]. This section explores the contributions of structural biology to RAS inhibitor discovery and highlights recent advancements in the field [17].

X-ray Crystallography

X-ray crystallography has been a cornerstone technique for determining the atomic-level structures of RAS proteins and their complexes with inhibitors [18]. The crystallization of RAS proteins in conjunction with small molecules allows researchers to observe the consistency of interactions and conformational changes that occur upon ligand binding. High-resolution RAS crystal structures available in the Protein Data Bank (PDB) are invaluable for structure-based chemical design [19]. Cases demonstrating the use of X-ray crystallography to guide the structure of RAS inhibitors highlight how this approach helps to elucidate structure-activity relationships and to purify copper compounds for enhanced selectivity the emphasis [17].

Cryo-Electron Microscopy (Cryo-EM)

A powerful approach to observing large macromolecular complexes, such as RAS signaling complexes and RAS-effector interactions is with cryo-electron microscopy, or cryo-EM [3]. Recent advancements in cryo-EM technology have enabled the determination of high-resolution structures of RAS proteins in complex with downstream effectors, shedding light on the spatial organization of RAS signaling complexes [17]. Cryo-EM reconstructions of RAS-effector complexes provide valuable insights into the allosteric regulation of RAS signaling and the mechanisms of effector engagement [16]. Integration of cryo-EM data with computational modeling approaches enhances our understanding of RAS-mediated signaling pathways and informs the design of allosteric RAS inhibitors targeting protein-protein interaction interfaces [12].

Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear magnetic resonance (NMR) spectroscopy offers complementary insights into the solution structures and dynamics of RAS proteins in solution [19]. By analyzing NMR spectra of isotopically labeled RAS proteins, researchers can characterize their conformational dynamics, ligand-binding kinetics, and interaction interfaces with high precision [20]. NMR studies have revealed conformational heterogeneity and transient interactions within the RAS protein family, providing mechanistic insights into their function and regulation [21]. Combined with computational modeling techniques, NMR-derived structural ensembles guide the rational design of allosteric RAS inhibitors and the optimization of lead compounds for improved pharmacological properties [17].

Structure-Based Drug Design

The integration of structural biology techniques with structure-based drug design (SBDD) approaches holds promise for the development of next-generation RAS inhibitors [19]. High-resolution structures of RAS proteins in complex with small molecule inhibitors provide a wealth of

information for rational drug design efforts. SBDD strategies leverage structural insights into RAS-ligand interactions to design novel compounds with improved binding affinity, selectivity, and pharmacokinetic properties [13]. Fragment-based drug design, virtual screening, and computational docking studies complement experimental structural biology data, enabling the rapid identification and optimization of lead compounds with therapeutic potential [15]. Case studies showcasing successful SBDD-guided discovery of RAS inhibitors demonstrate the impact of structural biology on accelerating drug discovery efforts and advancing precision oncology [19].

MACHINE LEARNING IN RAS INHIBITOR DISCOVERY

Machine learning (ML) approaches for computational drug design have proven to be powerful tools for the rapid and efficient discovery of RAS inhibitors. [14]. By leveraging large datasets and sophisticated algorithms, ML approaches enable the prediction of RAS protein-ligand interactions, modeling of structure-activity relationships (SAR), and prioritization of compound libraries for virtual screening [22]. This section explores the diverse applications of ML in RAS inhibitor discovery and highlights recent advancements in the field [16].

Introduction to Machine Learning

Machine learning, a branch of artificial intelligence (AI), aims to develop algorithms that can learn from data and make decisions or predictions without the need for explicit programming. Supervised, unsupervised, and reinforcement learning paradigms enable ML algorithms to extract patterns and relationships from training data, facilitating predictive modeling and decision-making tasks. Neural networks, deep learning architectures, random forests, and support vector machines (SVM) are common machine learning (ML) algorithms used in drug discovery [19].

Predicting RAS Protein-Ligand Interactions

Virtual screening and lead optimization efforts are facilitated using ML algorithms to predict the binding patterns and approaches of small molecule ligands to RAS proteins.13] Supervised learning models trained on experimental binding data learn to predict the binding affinity of novel compounds to RAS proteins based on their chemical features and structural properties [19]. Deep learning architectures, such as convolutional neural networks (CNN) and recurrent neural networks (RNN), capture complex interactions between ligands and proteins, enabling accurate prediction of protein-ligand binding modes [21].

Modeling Structure-Activity Relationships (SAR)

ML techniques are utilized to model SAR for RAS inhibitors, correlating chemical structure with biological activity to guide lead optimization and compound design. Physicochemical characteristics and molecular descriptors are used by quantitative structure-activity relationship (QSAR) models to forecast the potency, selectivity, and ADMET characteristics of RAS inhibitors. Machine learning-based SAR models enable the identification of structure-activity trends and the rational design of compounds with improved pharmacological profiles [19].

Ligand-Based and Structure-Based Virtual Screening

ML algorithms play a crucial role in ligand-based and structure-based virtual screening approaches for prioritizing compound libraries and identifying potential RAS inhibitors [14]. Ligand-based virtual screening methods, such as similarity searching and machine learning-based similarity metrics, identify structurally diverse compounds with favorable bioactivity profiles [17]. Structure-based screening methods combine ML models with molecular docking simulations to predict ligand binding and chemical reactions according to their expected binding to RAS proteins [11].

Deep Learning Approaches

RAS inhibitor discovery is increasingly using deep learning algorithms, such as recurrent neural networks (RNN), convolutional neural networks (CNN), and deep neural networks (DNN) [7]. Deep

learning models trained on large-scale chemical datasets learn complex representations of molecular structures and interactions, enabling de novo ligand design, molecular property prediction, and virtual screening tasks [16]. Deep learning-based approaches offer the potential to uncover novel RAS inhibitors with improved therapeutic profiles and guide rational drug design efforts [13].

Case Studies and Applications

Case studies and examples demonstrate the successful application of ML techniques in RAS inhibitor discovery, highlighting key insights gained, challenges encountered, and future directions [14]. ML-driven approaches have led to the identification of novel RAS inhibitors with potent activity and favorable pharmacological properties, accelerating drug discovery efforts and advancing precision oncology [19]. The integration of ML with experimental and computational methods offers a synergistic approach to drug discovery, enhancing the efficiency and effectiveness of RAS inhibitor discovery workflows [17].

RECENT ADVANCES AND CASE STUDIES

The latest advancements in RAS inhibitor discovery and showcase case studies illustrating innovative approaches and successful outcomes in the field. By examining recent breakthroughs and case examples, this section provides insights into the evolving landscape of RAS inhibitor research and its implications for cancer therapy [12].

Advances in Allosteric Inhibition

Recent studies have focused on targeting allosteric sites on RAS proteins, exploiting conformational changes and protein-protein interactions to modulate RAS signaling. Allosteric inhibitors designed to stabilize inactive RAS conformations or disrupt protein-protein interfaces have shown promise in preclinical models of RAS-driven cancers [12]. Case studies demonstrating the discovery and optimization of allosteric RAS inhibitors highlight their potential as novel therapeutics for inhibiting oncogenic RAS signaling [22].

Covalent Targeting Strategies

Advancements in covalent targeting strategies have enabled the development of irreversible inhibitors that covalently modify specific amino acid residues within RAS proteins. Covalent inhibitors leverage reactive cysteine residues in mutant RAS proteins to form irreversible bonds, leading to sustained inhibition of RAS signaling. Case studies showcasing the design and optimization of covalent RAS inhibitors demonstrate their potency, selectivity, and potential for overcoming drug resistance mechanisms in RAS-driven cancers [21].

Integration of Machine Learning and Structural Biology

Recent efforts have focused on integrating machine learning approaches with structural biology techniques to accelerate RAS inhibitor discovery. Machine learning algorithms trained on large-scale chemical datasets and structural databases enable the prediction of RAS protein-ligand interactions and the modeling of structure-activity relationships [19]. Case studies illustrating the synergistic combination of machine learning and structural biology highlight its utility in prioritizing compound libraries, guiding rational drug design, and accelerating lead optimization efforts [19].

Targeting RAS-Mutant Subtypes

Advances in understanding the molecular heterogeneity of RAS-mutant cancers have led to the identification of subtype-specific vulnerabilities and therapeutic targets. Recent studies have elucidated distinct signaling dependencies and vulnerabilities associated with different RAS mutations, paving the way for precision medicine approaches in RAS inhibitor discovery [22]. Case studies focusing on targeting specific RAS-mutant subtypes, such as KRAS G12C, NRAS Q61, and HRAS G12V, demonstrate the potential of subtype-specific inhibitors in overcoming therapeutic resistance and improving patient outcomes [12].

Combination Therapies and Resistance Mechanisms

Emerging evidence suggests that combination therapies targeting multiple nodes within the RAS pathway or synergistic signaling pathways may overcome therapeutic resistance and enhance the efficacy of RAS inhibitors [23]. Recent studies have explored the rationale for combining RAS inhibitors with inhibitors of downstream effectors, PI3K/AKT/mTOR pathway inhibitors, or immune checkpoint inhibitors. Case studies examining the mechanisms of resistance to RAS inhibitors and strategies to overcome resistance shed light on the complexities of RAS-driven cancers and the importance of rational combination therapies [17].

Clinical Translation and Future Perspectives

Advancements in RAS inhibitor discovery are increasingly translating into clinical trials, with several investigational compounds showing promising results in early-phase studies. Preclinical research has the potential to revolutionize cancer treatment and enhance patient outcomes when implemented in clinical settings [14]. Future perspectives encompass the continued optimization of RAS inhibitors, the development of predictive biomarkers for patient stratification, and the exploration of novel therapeutic modalities, such as antibody-drug conjugates and immunotherapies, in RAS-driven cancers [17, 18].

CONCLUSIONS

The discovery of effective inhibitors targeting the RAS pathway represents a critical milestone in cancer therapeutics, offering new hope for patients with RAS-driven malignancies. Over the years, significant progress has been made in leveraging computational methodologies, structural biology techniques, and innovative drug design strategies to accelerate RAS inhibitor discovery. This review provides a comprehensive summary of how computer-aided chemistry (CADD) has advanced RAS inhibitor research, highlighting recent advances, challenges, and opportunities in the field.

Through the integration of molecular modeling, virtual screening, machine learning, and structural biology approaches, researchers have gained invaluable insights into the structural and functional properties of RAS proteins and their interactions with small molecule inhibitors. Allosteric inhibition, covalent targeting strategies, and subtype-specific targeting have emerged as promising avenues for overcoming the challenges associated with traditional orthosteric inhibition of RAS proteins. The combination of technological and experimental approaches has enabled the evaluation and improvement of novel RAS inhibitors, resulting in increased potency, selectivity, and pharmacokinetics.

In conclusion, the continued collaboration between computational scientists, structural biologists, medicinal chemists, and clinicians is essential for accelerating the development and translation of RAS inhibitors into clinical practice. By harnessing the power of computer-aided drug design and innovative drug discovery approaches, we are poised to make significant strides in combating RAS-driven cancers and improving patient outcomes in the years to come.

REFERENCES

1. Kanwal S, Jamil F, Ali A, Sehgal SA. Comparative modeling, molecular docking, and revealing of potential binding pockets of RASSF2; a candidate cancer gene. Interdiscip Sci Comput Life Sci. 2017;9:214–223. doi:10.1007/s12539-016-0145-z.
2. Tuncbag N, Gursoy A, Nussinov R, Keskin O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc. 2011;6(9):1341–1354. doi:10.1038/nprot.2011.367.
3. Collier TA, Piggot TJ, Allison JR. Molecular Dynamics Simulation of Proteins. In: Gerrard J, Domigan L, editors. Protein Nanotechnology. Methods in Molecular Biology. New York: Humana; 2020. 311–327. doi:10.1007/978-1-4939-9869-2_17.

4. Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. Therapeutic targeting the allosteric cysteinome of RAS and kinase families. J Mol Biol. 2022;434(17):167626. doi:10.1016/j.jmb.2022.167626.
5. Prakash P, Sayyed-Ahmad A, Cho KJ, Dolino DM, Chen W, Li H, et al. Computational and biochemical characterization of two partially overlapping interfaces and multiple weak-affinity K-Ras dimers. Sci Rep. 2017;7(1):40109. doi:10.1038/srep40109.
6. Muratcioglu S, Chavan TS, Freed BC, Jang H, Khavrutskii L, Freed RN, et al. GTP-dependent K-Ras dimerization. Struct. 2015;23(7):1325–1335. doi:10.1016/j.str.2015.04.019.
7. Jisna VA, Jayaraj PB. Protein structure prediction: conventional and deep learning perspectives. Protein J. 2021;40(4):522–544. doi:10.1007/s10930-021-10003-y.
8. Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, et al. Improved protein structure prediction using potentials from deep learning. Nat. 2020;577(7792):706–710. doi:10.1038/s41586-019-1923-7.
9. Bhaskar BV, Rammohan A, Babu TM, Zheng GY, Chen W, Rajendra W, et al. Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies. Sci Rep. 2021;11(1):12150. doi:10.1038/s41598-021-90287-3.
10. Parca L, Mangone I, Gherardini PF, Ausiello G, Helmer-Citterich M. Phosfinder: a web server for the identification of phosphate-binding sites on protein structures. Nucleic acids research. 2011;39(suppl_2):W278–282. doi:10.1093/nar/gkr389.
11. Singh H, Srivastava HK, Raghava GP. A web server for analysis, comparison and prediction of protein ligand binding sites. Biol Direct. 2016;11:1–4. doi:10.1186/s13062-016-0118-5.
12. Cox AD, Der CJ. Ras history: The saga continues. Small GTPases. 2010;1(1):2–27. doi:10.4161/sgtp.1.1.12178.
13. Konc J, Skrlj B, Erzen N, Kunej T, Janezic D. GenProBiS: web server for mapping of sequence variants to protein binding sites. Nucleic Acids Res. 2017;45(W1):W253–259. doi:10.1093/nar/gkx420.
14. Wang Y, Lupala CS, Liu H, Lin X. Identification of drug binding sites and action mechanisms with molecular dynamics simulations. Curr Top Med Chem. 2018;18(27):2268–2277. doi:10.2174/1568026619666181212102856.
15. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling. Nat. 2013;497(7451):638–642. doi:10.1038/nature12205.
16. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nat. 2013;503(7477):548–551. doi:10.1038/nature12796.
17. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nat. 2019;575(7781):217–223. doi:10.1038/s41586-019-1694-1.
18. Hernandez M, Ghersi D, Sanchez R. SITEHOUND-web: a server for ligand binding site identification in protein structures. Nucleic Acids Res. 2009;37(suppl_2):W413–416. doi:10.1093/nar/gkp281.
19. Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem. 2014;289(20):13717–13125. doi:10.1074/jbc.M113.511030.
20. Zhu M, Gribskov M. MiPepid: MicroPeptide identification tool using machine learning. BMC Bioinform. 2019;20:1–1. doi:10.1186/s12859-019-3033-9.
21. Langer MF, Goeßmann A, Rupp M. Representations of molecules and materials for interpolation of quantum-mechanical simulations via machine learning. Comput Mater. 2022;8(1):41. doi:10.1038/s41524-022-00721-x.

22. Keith JA, Vassilev-Galindo V, Cheng B, Chmiela S, Gastegger M, Muller KR, et al. Combining machine learning and computational chemistry for predictive insights into chemical systems. Chem Rev. 2021;121(16):9816–98172. doi:10.1021/acs.chemrev.1c00107.
23. Nguyen TH, Thai QM, Pham MQ, Minh PT, Phung HT. Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds. Mol Divers. 2024;28(2):553–561. doi:10.1007/s11030-023-10601-1.

